**Supplemental Table 1.** Grade 3 and above treatment-related adverse events in the study. AST, Aspartate transaminase.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| N (%) | All | Grade 3 | Grade 4 | Grade 5 |
| All Grade 3 and above | 25 (19.5) | 13 (10.2) | 12 (9.4) | 0 |
| Amylase increased | 5 (3.9) | 2 (1.6) | 3 (2.3) | 0 |
| Creatine kinase increased | 4 (3.1) | 2 (1.6) | 2 (1.6) | 0 |
| Lipase increased | 4 (3.1) | 2 (1.6) | 2 (1.6) | 0 |
| Hypertriglyceridemia | 3 (2.3) | 2 (1.6) | 1 (0.8) | 0 |
| Liver injury | 2 (1.6) | 0 | 2 (1.6) | 0 |
| Hyponatremia | 2 (1.6) | 2 (1.6) | 0 | 0 |
| Thrombocytopenia | 2 (1.6) | 0 | 2 (1.6) | 0 |
| Hypochloremia | 2 (1.6) | 2 (1.6) | 0 | 0 |
| Hyperglycemia | 2 (1.6) | 1 (0.8) | 1 (0.8) | 0 |
| Elevated liver transaminase | 1 (0.8) | 0 | 1 (0.8) | 0 |
| Uveitis | 1 (0.8) | 1 (0.8) | 0 | 0 |
| AST increased | 1 (0.8) | 1 (0.8) | 0 | 0 |
| Interstitial lung disease | 1 (0.8) | 1 (0.8) | 0 | 0 |
| Neutropenia | 1 (0.8) | 1 (0.8) | 0 | 0 |
| Urine ketone present | 1 (0.8) | 0 | 1 (0.8) | 0 |
| Hypokalemia | 1 (0.8) | 1 (0.8) | 0 | 0 |
| Cortisol levels decreased | 1 (0.8) | 1 (0.8) | 0 | 0 |